Key Takeaways
  • For healthy adults, the big trials are mostly flat: in VITAL, 2,000 IU a day for a median 5.3 years brought no fewer cancers, major cardiovascular events or fractures among 25,871 Americans
  • Big, infrequent doses aren't better and can backfire: 500,000 IU once a year led to 15% more falls and 26% more fractures in women aged 70 and over
  • The Endocrine Society (2024) suggests extra vitamin D for ages 1 to 18, adults 75 and over, pregnancy and high-risk prediabetes, and suggests against routine blood tests
  • Some people are more likely to run low: diagnosed deficiency, little sun, darker skin at high latitudes, conditions that limit fat absorption and some medicines
  • Dose: the US recommended intake is 600 IU a day to age 70 and 800 IU after; the adult upper limit is 4,000 IU

The days are shorter, the sun is lower and the vitamin D bottles are back by the checkout. Several very large randomised trials have now tested whether the pills actually prevent disease. It isn't medical advice: if you have a health condition or take regular medicines, talk to your doctor before starting or changing a supplement.

0.96
Hazard ratio for invasive cancer with 2,000 IU of vitamin D a day vs placebo in VITAL (25,871 US adults): no significant difference (New England Journal of Medicine, 2019)
Part one · The big trials

What the Big Trials Found

Evidence: Large randomised trials — mostly no benefit

VITAL: 2,000 IU a day

VITAL randomised 25,871 US men aged 50 and over and women aged 55 and over to 2,000 IU of vitamin D3 a day or a placebo (the trial also tested omega-3 in a factorial design). After a median 5.3 years, there were 793 invasive cancers in the vitamin D group and 824 in the placebo group, a hazard ratio of 0.96 (95% CI 0.88 to 1.06). Major cardiovascular events (heart attack, stroke or cardiovascular death) numbered 396 vs 409, a hazard ratio of 0.97 (0.85 to 1.12). The authors concluded that vitamin D "did not result in a lower incidence of invasive cancer or cardiovascular events than placebo" (Manson, NEJM 2019).

One caveat: VITAL didn't select people who were short of vitamin D. Among participants with a blood test at the start, average 25-hydroxyvitamin D (25(OH)D, the standard test) was 30.7 ng/mL, above the 20 ng/mL (50 nmol/L) that the NIH Office of Dietary Supplements (ODS) says is "generally considered adequate" (LeBoff, NEJM 2022; NIH ODS).

D-Health: 60,000 IU a month

The D-Health trial gave 21,315 Australians aged 60 to 84 either 60,000 IU of vitamin D3 once a month or a placebo for up to five years. Blood levels averaged 115 nmol/L with vitamin D and 77 nmol/L on placebo. Deaths were 562 (5.3%) with vitamin D and 538 (5.1%) with placebo, a hazard ratio of 1.04 (0.93 to 1.18). The authors' verdict: "Administering vitamin D3 monthly to unscreened older people did not reduce all-cause mortality" (Neale, Lancet Diabetes Endocrinol 2022).

A 2023 D-Health analysis found 637 major cardiovascular events (6.0%) with vitamin D and 699 (6.6%) with placebo, a hazard ratio of 0.91 (0.81 to 1.01). Heart attacks were lower (0.81, 0.67 to 0.98); strokes were not. That is 172 people treated for five years to prevent one event, and the authors noted that "the confidence interval was consistent with a null finding" (Thompson, BMJ 2023).

ViDA: 100,000 IU a month

ViDA randomised 5,110 New Zealanders aged 50 to 84 to 200,000 IU of vitamin D3 and then 100,000 IU monthly, or a placebo. After a median 3.3 years, 303 (11.8%) on vitamin D and 293 (11.5%) on placebo had a cardiovascular event, a hazard ratio of 1.02 (0.87 to 1.20). "Monthly high-dose vitamin D supplementation does not prevent CVD," the authors concluded (Scragg, JAMA Cardiology 2017).

DO-HEALTH: 2,000 IU a day in Europeans over 70

DO-HEALTH enrolled 2,157 people aged 70 and over living at home in five European countries. Their average starting level was 22.4 ng/mL, and about 40% were below 20 ng/mL. Over three years, 2,000 IU a day made no significant difference to blood pressure, physical performance, thinking scores, non-vertebral fractures (incidence rate ratio 1.03) or infections (0.95). The findings "do not support the effectiveness" of vitamin D, omega-3 or a home strength programme "for these clinical outcomes" (Bischoff-Ferrari, JAMA 2020).

A 2025 post hoc analysis of 777 participants used four DNA methylation "clocks" of biological ageing. "Omega-3 alone slowed the DNAm clocks PhenoAge, GrimAge2 and DunedinPACE," with extra benefit on one clock when all three interventions were combined. No effect was reported for vitamin D on its own, and the effects were small, about 3 to 4 months over three years (University of Zurich; Bischoff-Ferrari, Nature Aging 2025). Our guide to biological age tests explains why these numbers are softer than they look.

Figure 1 · Randomised trials

Main results, vitamin D vs placebo

Hazard or rate ratio (95% CI) ← fewer events · more events → 0.5 1.0 1.5 VITAL · invasive cancer 2,000 IU daily · 0.96 (0.88–1.06) VITAL · major CV events 2,000 IU daily · 0.97 (0.85–1.12) VITAL · death, any cause 2,000 IU daily · 0.99 (0.87–1.12) VITAL · fractures 2,000 IU daily · 0.98 (0.89–1.08) VITAL · autoimmune disease 2,000 IU daily · 0.78 (0.61–0.99) D-Health · death, any cause 60,000 IU monthly · 1.04 (0.93–1.18) D-Health · major CV events 60,000 IU monthly · 0.91 (0.81–1.01) ViDA · cardiovascular disease 100,000 IU monthly · 1.02 (0.87–1.20) Sanders · falls 500,000 IU yearly · 1.15 (1.02–1.30)

A ratio below 1.0 means fewer events with vitamin D; a line that crosses 1.0 means no statistically significant difference. Gold: significant benefit. Rust: significant harm. Sources: Manson, NEJM 2019; LeBoff, NEJM 2022; Hahn, BMJ 2022; Neale, Lancet Diabetes Endocrinol 2022; Thompson, BMJ 2023; Scragg, JAMA Cardiol 2017; Sanders, JAMA 2010 (incidence rate ratio). Major cardiovascular (CV) events in D-Health include coronary revascularisation; ViDA counts all cardiovascular disease events.

Part two · Bones and falls

Bones, Falls and Fractures

Evidence: Randomised trials — no benefit in healthy adults

Vitamin D helps the body absorb calcium, so bones were the obvious place to look. In VITAL, 769 of 12,927 people on vitamin D and 782 of 12,944 on placebo had a fracture, a hazard ratio of 0.98 (0.89 to 1.08); hip fractures were no different (1.01). The result applies to "generally healthy midlife and older adults who were not selected for vitamin D deficiency, low bone mass, or osteoporosis" (LeBoff, NEJM 2022). In ViDA, 51.7% of the vitamin D group and 52.7% of the placebo group had at least one fall, and the authors concluded that their monthly regimen "does not prevent falls or fractures in this healthy ambulatory adult population" (Khaw, Lancet Diabetes Endocrinol 2017).

The US Preventive Services Task Force (USPSTF) agrees. Its 2018 statement recommends against daily supplementation with 400 IU or less of vitamin D and 1,000 mg or less of calcium to prevent fractures in postmenopausal women living at home, finds the evidence insufficient for higher doses, men and premenopausal women, and notes that vitamin D with calcium "increases the incidence of kidney stones." It doesn't apply to people with osteoporosis, a past osteoporotic fracture or vitamin D deficiency (USPSTF 2018). A December 2024 draft, still not finalised as of November 2026, goes further: it recommends against vitamin D, with or without calcium, to prevent fractures, and against vitamin D to prevent falls, in postmenopausal women and men aged 60 and over who live at home. It doesn't apply to people with osteoporosis or vitamin D deficiency (USPSTF draft, 2024). If bones are your worry, ask your doctor about osteoporosis screening, and see our guide to building muscle after 40.

When a big dose backfired

In one randomised trial, 2,256 women aged 70 and over at high risk of fracture took 500,000 IU of vitamin D3 or a placebo once a year, each autumn or winter, for three to five years. The vitamin D group had 15% more falls (incidence rate ratio 1.15, 95% CI 1.02 to 1.30) and 26% more fractures (1.26, 1.00 to 1.59), with falls 31% more frequent in the first three months after a dose (Sanders, JAMA 2010).

Part three · The hopeful signals

Cancer Deaths, Autoimmunity and Other Hints

Evidence: Secondary analyses — hypothesis-generating

In VITAL, cancer deaths were 17% lower with vitamin D (hazard ratio 0.83, 0.67 to 1.02), which wasn't statistically significant. Excluding the first two years of follow-up, it was 0.75 (0.59 to 0.96) (Manson, VITAL principal results). A 2020 secondary analysis found fewer metastatic or fatal cancers (hazard ratio 0.83, 0.69 to 0.99), with the "strongest risk reduction seen in individuals with normal weight" (Chandler, JAMA Netw Open 2020). Manson called the post hoc findings "hypothesis-generating" (TCTMD).

D-Health pointed the other way. Cancer deaths were slightly higher with monthly vitamin D (1.15, 0.96 to 1.39), and in an exploratory analysis excluding the first two years the hazard ratio was 1.24 (1.01 to 1.54) (Neale 2022). The trials used different dosing schedules, but the conflict is a reason for caution.

The most interesting signal is autoimmune disease. In VITAL, confirmed autoimmune diseases, such as rheumatoid arthritis, autoimmune thyroid disease and psoriasis, occurred in 123 people on vitamin D and 155 on placebo, a hazard ratio of 0.78 (0.61 to 0.99), a 22% reduction. Excluding the first two years, it was 0.61 (0.43 to 0.86). But the main result only just reached significance (P=0.05), and no single disease did on its own (Hahn, BMJ 2022).

The headlineVitamin D cuts cancer deaths, heart attacks and autoimmune disease.
What the evidence showsThe trials' main results were flat. The positive findings come from secondary analyses, and D-Health hinted the opposite for cancer deaths. Worth studying, not a reason for healthy adults to take high doses.
Part four · The guidelines

What the Guidelines Say

Evidence: Official guidance

The Endocrine Society's 2024 guideline, led by Marie Demay, defines "empiric" supplementation as intake that "exceeds the Dietary Reference Intakes (DRI)," given without a blood test. It suggests empiric vitamin D for four groups: "children and adolescents aged 1 to 18 years" to prevent rickets and possibly respiratory infections; adults aged 75 and older "because of its potential to lower the risk of mortality"; pregnancy, because of "its potential to lower the risk of preeclampsia," preterm birth and other complications; and, alongside lifestyle changes, "high-risk prediabetes because of its potential to reduce progression to diabetes." For healthy adults under 75, it "suggests against empiric vitamin D supplementation above the current DRI" (Demay, J Clin Endocrinol Metab 2024).

For adults over 50 who need vitamin D, the panel suggests "daily administration of vitamin D, rather than intermittent use of high doses." And it "suggests against routine 25(OH)D testing in the absence of established indications," having found "No clinical trial evidence" to support routine screening (Demay 2024). Our guide to blood tests after 40 covers which tests are worth asking for.

Figure 2 · Who benefits

Who should consider vitamin D, and how strong the case is

GroupWhat the evidence saysStrength
Diagnosed deficiency below 30 nmol/L (12 ng/mL)The ODS threshold for deficiency; treatment is a medical decisionClear: treat with your doctor
Conditions that limit fat absorption, gastric bypassThe ODS says some "might therefore require vitamin D supplementation"Clear: doctor-led
Little sun: housebound, care homes, skin coveredUK advice: 10 mcg (400 IU) a day all yearOfficial advice NHS
Darker skin at high latitudesUK advice: consider 10 mcg a day all year. Lower blood levels are common, but health consequences are "not clear"Official advice NHS; outcome data thin
Ages 1–18Rickets; possibly fewer respiratory infectionsGuideline suggestion Endocrine Society 2024; low-certainty evidence
Age 75 and overPotential to lower mortality; prefer daily dosesGuideline suggestion Endocrine Society 2024; moderate-certainty evidence
PregnancyPotential to lower risk of preeclampsia, preterm birth and other complicationsGuideline suggestion Endocrine Society 2024; low-certainty evidence
High-risk prediabetesPotential to reduce progression to diabetes, alongside lifestyle changesGuideline suggestion Endocrine Society 2024; moderate-certainty evidence
Healthy adults under 75Main results flat in large trials of mostly healthy adults aged 50 and over (VITAL, D-Health, ViDA, DO-HEALTH); guideline suggests against doses above the DRILittle or no benefit above the RDA
Preventing falls or fractures in healthy older adultsNo benefit in trials; very large yearly doses increased bothRecommended against USPSTF 2024 draft; 2018 final covered low doses in postmenopausal women

Sources: NIH Office of Dietary Supplements fact sheet; NHS; Demay et al., J Clin Endocrinol Metab 2024; USPSTF. "Guideline suggestion" means a conditional recommendation, not a requirement. Ask your doctor what applies to you.

Part five · Who needs it

Who Is Most Likely to Run Low

Evidence: Official guidance and clinical reasoning

Healthy-volunteer trials say little about people who are actually short of vitamin D. In US survey data from 2011 to 2014, 5% of people were at risk of deficiency (below 30 nmol/L, or 12 ng/mL) and 18% at risk of inadequacy (30 to 49 nmol/L), according to the ODS, which lists the groups most likely to fall short (NIH ODS):

For everyone else, the UK takes a seasonal approach: everyone "should consider taking a daily supplement containing 10 micrograms of vitamin D in autumn and winter," because in spring and summer "the majority of the population get enough vitamin D through sunlight on the skin" (Public Health England, 2016). That modest dose is below the US recommended intake and aims to prevent deficiency, not cancer or heart disease.

Part six · Dose and safety

How Much Is Too Much?

Evidence: Official guidance

The US Recommended Dietary Allowance (RDA) for adults is 600 IU (15 micrograms) a day up to age 70 and 800 IU (20 micrograms) after that. The Tolerable Upper Intake Level for adults is 4,000 IU (100 micrograms) a day from all sources. In US survey data from 2015 to 2016, average intakes from food and drink were only 204 IU a day in men and 168 IU in women (NIH ODS).

"Vitamin D toxicity is almost always a result of excessive intakes of vitamin D through supplements," the ODS says, and experts don't believe sun exposure causes it. Too much raises blood calcium, which can cause nausea, vomiting, muscle weakness, "neuropsychiatric disturbances," dehydration and kidney stones. Symptoms are unlikely below 10,000 IU a day, but the expert panel behind the US limits noted that even intakes below the upper limit "might have adverse health effects over time," and that blood levels above 125 nmol/L (50 ng/mL) "can be associated with adverse effects." The NHS says: "Do not take more than 100 micrograms (4,000 IU) of vitamin D a day as it could be harmful."

Figure 3 · NIH Office of Dietary Supplements

Vitamin D in food, per serving

FoodServingVitamin D
Cod liver oil1 tablespoon1,360 IU
Trout, farmed, cooked3 oz (85 g)645 IU
Salmon, sockeye, cooked3 oz (85 g)570 IU
White mushrooms, raw, sliced, UV-exposed½ cup366 IU
Milk, 2%, fortified1 cup120 IU
Soy, almond or oat drink, fortified1 cup100–144 IU
Breakfast cereal, fortified 10% Daily Value1 serving80 IU
Sardines, canned in oil2 sardines46 IU
Egg, scrambled1 large44 IU
Tuna, light, canned in water3 oz (85 g)40 IU
Cheddar cheese1.5 oz (43 g)17 IU
US RDA, adults to 70 / over 70per day600 / 800 IU
Upper limit, adultsper day4,000 IU

NIH Office of Dietary Supplements, Vitamin D Fact Sheet for Health Professionals (food table, RDAs and upper limit). 1 microgram = 40 IU. Fortification varies by brand and country, so check the label. Metric weights are rounded conversions.

Part seven · What to do

A Sensible Winter Plan

Frequently Asked Questions

Should I take a vitamin D supplement in winter?
UK advice is for everyone to consider 10 micrograms (400 IU) a day in autumn and winter, and all year if you get little sun or have dark skin. In large trials, extra vitamin D didn't prevent cancer, heart disease or fractures in healthy adults. If you're 75 or older, pregnant or have a health condition, ask your doctor.
Does vitamin D prevent cancer or heart disease?
Not in healthy adults, on current evidence. In the VITAL trial of 25,871 US adults, 2,000 IU a day for a median 5.3 years didn't lower invasive cancer (hazard ratio 0.96) or major cardiovascular events (0.97). There were hints of fewer cancer deaths, but they came from secondary analyses.
Should I get my vitamin D level tested?
Not routinely if you're healthy. The Endocrine Society's 2024 guideline suggests against routine 25-hydroxyvitamin D testing in the absence of established indications. Testing makes sense if your doctor suspects deficiency or you have a condition that affects how you absorb it.
How much vitamin D is too much?
The US upper limit for adults is 4,000 IU (100 micrograms) a day from all sources. Toxicity almost always comes from supplements, not sun. Blood levels above 125 nmol/L (50 ng/mL) can be associated with adverse effects.
Is a big weekly or monthly dose as good as a daily one?
Guidelines prefer daily. For adults over 50 who need vitamin D, the Endocrine Society suggests daily, lower doses rather than intermittent high doses. In one trial of 2,256 women aged 70 or over, 500,000 IU once a year led to 15% more falls and 26% more fractures than placebo.
The Bottom Line

Useful for some, not a cure-all.

For healthy adults who aren't deficient, the largest trials found that extra vitamin D didn't prevent cancer, heart disease, fractures or early death. Hints of fewer cancer deaths and autoimmune diseases are unconfirmed, and big infrequent doses can do harm.

It clearly matters if you have diagnosed deficiency or a condition that limits absorption. People who get little sun, have darker skin at high latitudes or take certain medicines are more likely to run low, and the Endocrine Society suggests it for children, people 75 and over, pregnancy and high-risk prediabetes. If that's you, talk to your doctor. For everyone else, a modest daily dose in winter is reasonable, but it isn't a longevity strategy.

Sources

  1. Manson JE, et al. Vitamin D supplements and prevention of cancer and cardiovascular disease. New England Journal of Medicine 2019;380(1):33–44 (doi:10.1056/NEJMoa1809944). See also TCTMD coverage.
  2. Manson JE, et al. Principal results of the VITamin D and OmegA-3 TriaL (VITAL) and updated meta-analyses of relevant vitamin D trials. Journal of Steroid Biochemistry and Molecular Biology, published online November 2019.
  3. Chandler PD, et al. Effect of vitamin D3 supplements on development of advanced cancer: a secondary analysis of the VITAL randomized clinical trial. JAMA Network Open 2020;3(11):e2025850 (doi:10.1001/jamanetworkopen.2020.25850).
  4. Hahn J, Cook NR, Alexander EK, et al. Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial. BMJ 2022;376:e066452 (doi:10.1136/bmj-2021-066452).
  5. LeBoff MS, Chou SH, Ratliff KA, et al. Supplemental vitamin D and incident fractures in midlife and older adults. New England Journal of Medicine 2022;387(4):299–309 (doi:10.1056/NEJMoa2202106).
  6. Neale RE, et al. The D-Health Trial: a randomised controlled trial of the effect of vitamin D on mortality. Lancet Diabetes & Endocrinology 2022;10(2):120–128 (doi:10.1016/S2213-8587(21)00345-4).
  7. Thompson B, Waterhouse M, English DR, et al. Vitamin D supplementation and major cardiovascular events: D-Health randomised controlled trial. BMJ 2023;381:e075230, published 28 June 2023.
  8. Scragg R, Stewart AW, Waayer D, et al. Monthly high-dose vitamin D and cardiovascular disease in the Vitamin D Assessment (ViDA) Study. JAMA Cardiology 2017;2(6):608–616 (doi:10.1001/jamacardio.2017.0175). Summary via PACE-CME.
  9. Khaw KT, et al. Monthly high-dose vitamin D, falls and non-vertebral fractures in the ViDA trial. Lancet Diabetes & Endocrinology 2017 (doi:10.1016/S2213-8587(17)30103-1; accepted manuscript, University of Cambridge repository).
  10. Bischoff-Ferrari HA, Vellas B, Rizzoli R, et al. Effect of vitamin D supplementation, omega-3 fatty acid supplementation, or a strength-training exercise program on clinical outcomes in older adults: the DO-HEALTH randomized clinical trial. JAMA 2020;324(18):1855–1868 (doi:10.1001/jama.2020.16909).
  11. Bischoff-Ferrari HA, et al. Individual and additive effects of vitamin D, omega-3 and exercise on DNA methylation clocks of biological aging in older adults from the DO-HEALTH trial. Nature Aging 2025;5(3):376–385 (doi:10.1038/s43587-024-00793-y). Abstract via Europe PMC; University of Zurich news release.
  12. Sanders KM, et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA 2010;303(18):1815–1822 (doi:10.1001/jama.2010.594). See also JAMA news release.
  13. Demay MB, Pittas AG, Bikle DD, et al. Vitamin D for the prevention of disease: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism 2024;109(8):1907–1947 (doi:10.1210/clinem/dgae290).
  14. Endocrine Society. Endocrine Society recommends healthy adults take the recommended daily allowance of vitamin D. 3 June 2024.
  15. NIH Office of Dietary Supplements. Vitamin D: Fact Sheet for Health Professionals. Accessed November 2026.
  16. US Preventive Services Task Force. Vitamin D, Calcium, or Combined Supplementation for the Primary Prevention of Fractures in Adults: Preventive Medication. 17 April 2018.
  17. US Preventive Services Task Force. Draft recommendation bulletin: vitamin D, calcium, or combined supplementation to prevent falls and fractures. Posted for comment 17 December 2024.
  18. NHS. Vitamin D. Accessed November 2026.
  19. Public Health England. PHE publishes new advice on vitamin D. 21 July 2016.